Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First

What happened: A Seeking Alpha analyst rates Nanobiotix S.A. a Hold, noting the company now depends primarily on J&J's development and commercialization of its lead asset, JNJ-1900. Key numbers: J&J's timeline suggests main Phase 3 data may arrive in mid-2028, later than company guidance. Why it matters: The analyst cites delayed catalysts, lender claims on near-term milestone payments, and a share price that appears to price in Phase 3 success.

A Seeking Alpha analyst rates Nanobiotix S.A. a Hold, noting the company now depends primarily on J&J's development and commercialization of its lead asset, JNJ-1900.

The analyst cites delayed catalysts, lender claims on near-term milestone payments, and a share price that appears to price in Phase 3 success.